• Home
  • News
  • Nursing Education
    • NCLEX
    • NP/PA
    • RN/LPN/LVN
    • CMA/CNA/HHA
    • SCHOLARSHIPS
  • Community
  • Hospitals
  • Regulation
  • Shopping Deals
Sunday, January 24, 2021
NCLEXION!
  • Home
  • News
  • Nursing Education
    • NCLEX
    • NP/PA
    • RN/LPN/LVN
    • CMA/CNA/HHA
    • SCHOLARSHIPS
  • Community
  • Hospitals
  • Regulation
  • Shopping Deals
No Result
View All Result
  • Home
  • News
  • Nursing Education
    • NCLEX
    • NP/PA
    • RN/LPN/LVN
    • CMA/CNA/HHA
    • SCHOLARSHIPS
  • Community
  • Hospitals
  • Regulation
  • Shopping Deals
NCLEXION.COM
No Result
View All Result
Home Hospital

Patients told to exchange faulty adrenaline pen brand for alternative

May 21, 2020
in Hospital
0
Patients told to exchange faulty adrenaline pen brand for alternative
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Warning: Invalid argument supplied for foreach() in /home/nclexion/public_html/wp-content/themes/jnews/class/ContentTag.php on line 47

Allergy patients who carry a particular type of adrenaline auto-injector pen that has been found to be faulty should be advised to seek replacement pens of a different brand, according to safety regulators.

The Medicines and Healthcare products Regulatory Agency (MHRA) said healthcare professionals were being asked to contact patients who use Emerade 500 microgram pens.

Both patients and carers should return all Emerade 500 micrograms auto-injectors to their local pharmacy once they have obtained a prescription for, and been supplied with, an alternative brand, said the MHRA.

“It is vital that patients follow existing advice to carry two pens with them at all times”

MHRA spokesperson

The recall has been sparked by reports of difficulty in activating the pens, meaning the dose of adrenaline may not be delivered when needed by a patient for anaphylaxis.

The MHRA’s alert stated: “Results from manufacturer testing of Emerade auto-injectors recalled from patients in Europe indicate that approximately 13% of pens need higher than normal force to activate, implying a higher risk of activation failure than was previously understood.”

Most of the pens will still activate, but more force may need to be applied, warned the MHRA. The recall of Emerade 500 microgram auto-injectors also follows the previous recalls of Emerade 150 and 300 microgram auto-injectors.

The pens were recalled in three phases to ensure there would be enough supplies of the alternative pens, EpiPen or Jext, available for patients, noted the MHRA.

It highlighted that alternative brands of adrenaline auto-injector (EpiPen and Jext) were available in a maximum strength of 300 micrograms.

Emerade 500mcg auto-injectors

The MHRA said data showed that a single EpiPen (300 microgram) or Jext (300 microgram) pen would be a “suitable replacement” for a single Emerade 500 microgram pen.

This is based on results from a study that compared blood levels of adrenaline following EpiPen 300 micrograms or Jext 300 micrograms with that following Emerade 500 micrograms.

An MHRA spokesperson said: “Action has been taken to protect patients, following detection of a fault in one component of the Emerade adrenaline auto-injector pens.”

They said patients should be advised to return all relevant pens to their local pharmacy once they have a new prescription and had been supplied with pens of an alternative brand.

“It is vital that patients follow existing advice to carry two pens with them at all times and to contact their doctor when a replacement is due,” the spokesperson.

“When switching to a different brand of adrenaline pen, the patient must ensure they are familiar with how to use the pen as each brand is administered differently,” they added.

But, given the Covid-19 crisis, the MHRA advised that healthcare professionals were unlikely to be able to help with face to face training but there may be opportunities for remote consultations.

“Action has been taken to protect patients, following detection of a fault in one component of the Emerade adrenaline auto-injector pens”

MHRA spokesperson

Patients must be encouraged to take particular care to read the instructions on how to use the new pen which can be found in the leaflet contained in the box, the MHRA noted.

It highlighted that the manufacturers’ websites for each brand of pen had information and training videos, while trainer pens could be obtained from the manufacturer.

The MHRA added that, if an Emerade pen did need to be used before a patient was able to obtain an alternative pen, it should be pressed very firmly against the thigh.

“If this does not result in activation, the patient should immediately use their second pen,” warned the authority in its safety alert.

Previous Post

Nurse Practitioners: Opening Your Own Practice

Next Post

Attacks against nurses ‘must be condemned’ as world fights Covid-19

Next Post
Attacks against nurses ‘must be condemned’ as world fights Covid-19

Attacks against nurses ‘must be condemned’ as world fights Covid-19

Discussion about this post

Recommended

Celebrate Forensic Nurses Day Today

1 year ago
‘As students face uncertainty, Nursing Times will support them’

‘Action must now be taken to stamp out inequality’

7 months ago

Don't Miss

RCN Congress 2020 cancelled due to coronavirus pandemic

RCN confirms new date for congress 2021 and aims for in-person event

January 22, 2021
‘COVID-NURSE’ trial to create standard model for nursing Covid-19 patients

Covid-19 treatment roll-out going ahead despite contradictory study

January 22, 2021
Covid-19 workforce pressures see creation of new support role

Covid-19 workforce pressures see creation of new support role

January 22, 2021
CNO recruits first-ever social care advisor to her top team

Social care chief nurse urges workforce to take up Covid-19 vaccine

January 21, 2021
NCLEXION!

PLEASE, FOLLOW US ON SOCIAL MEDIA AND SHARE OUR LIFESAVING ARTICLES TO THOSE WHO MAY NOT BE IN THE HEALTHCARE INDUSTRY!

Follow us

Recent News

RCN Congress 2020 cancelled due to coronavirus pandemic

RCN confirms new date for congress 2021 and aims for in-person event

January 22, 2021
‘COVID-NURSE’ trial to create standard model for nursing Covid-19 patients

Covid-19 treatment roll-out going ahead despite contradictory study

January 22, 2021

Categories

  • Community
  • Hospital
  • National Council Licensure Examination (NCLEX)
  • News
  • Nursing School
  • Nursing Students
  • Regulation

Tags

Health Symptoms hospital Men's Health nclexion nurrsing news nurse nursing news nursing school nursing students rn to bsn rn to bsn online Women's Health
  • Contact
  • Privacy Policy
  • About Us

© 2019 NCLEXION! - Nursing Students & Professional Nurses' News Portal!

No Result
View All Result
  • Home
  • News
  • Nursing Education
    • NCLEX
    • NP/PA
    • RN/LPN/LVN
    • CMA/CNA/HHA
    • SCHOLARSHIPS
  • Community
  • Hospitals
  • Regulation
  • Shopping Deals

© 2019 NCLEXION! - Nursing Students & Professional Nurses' News Portal!

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In